Ketogenic diet as possible therapy of autism spectrum disorder — review and implication

Authors

  • Aleksander Rajczewski
  • Magdalena Gibas-Dorna Department of Physiology, Poznan University of Medical Sciences, Swiecickiego 6, 60-781 Poznan,

DOI:

https://doi.org/10.20883/jms.297

Keywords:

autism spectrum disorder, ketogenic diet, autism, dietary approach

Abstract

Autism spectrum disorder (ASD) has become widespread neurodevelopmental disorder, which currently can be treated with only few therapeutic options. Furthermore, their effectiveness is limited therefore novel treatment strategies for ASD are needed. This review seeks to address this need by discussing a ketogenic diet (KD) in the context of ASD therapy. KD effects have been examined in animal and human studies. They indicate effectiveness of KD by improving autistic features. Moreover, animal studies have revealed clinically useful information about caloric restriction component of KD, which is not necessary to achieve therapeutic effects. Significantly administration of KD but not β-hydroxybutyrate or acetone has a therapeutic effect on social interactions. Human studies are scarce, however previous researches imply KD as an effective treatment at least in certain types of autism. KD in an altered form as: modified Atkins diet (MAD), ketogenic gluten-free diet with supplemental medium-chain triglyceride (MCT), and John Radcliffe ketogenic diet is an alternative to classic KD. These variants provide better quality of nutrition and are less strict, thus less difficult to maintain. KD is described as safe with limited, easily manageable adverse effects. Taken together human and animal studies would seem to suggest that KD will become part of ASD treatment. However, in order to determine accurate recommendations for all ASD patients, further studies are required.

Downloads

Download data is not yet available.

References

NIMH Autism Spectrum Disorder [Internet]. [cited 2018 Mar 31]. Available from: https://www.nimh.nih.gov/health/topics/autism‑spectrum‑disorders‑asd/index.shtml#part_145441.

Park HR, Lee JM, Moon HE, Lee DS, Kim B‑N, Kim J, et al. A Short Review on the Current Understanding of Autism Spectrum Disorders. Exp Neurobiol. 2016 Feb;25(1):1–13.

Sweeten TL, Posey DJ, Shekhar A, McDougle CJ. The amygdala and related structures in the pathophysiology of autism. Pharmacology Biochemistry and Behavior. 2002 Mar 1;71(3):449–55.

Bölte S. Is autism curable? Dev Med Child Neurol. 2014 Oct;56(10):927–31.

Martin K, Jackson CF, Levy RG, Cooper PN. Ketogenic diet and other dietary treatments for epilepsy. In: The Cochrane Library [Internet]. John Wiley & Sons, Ltd; 2016 [cited 2018 Apr 1]. Available from: http://cochranelibrary‑wiley.com/doi/10.1002/14651858.CD001903.pub3/full.

Li H‑F, Zou Y, Ding G. Therapeutic Success of the Ketogenic Diet as a Treatment Option for Epilepsy: a Meta‑analysis. Iran J Pediatr. 2013 Dec;23(6):613–20.

Araya‑Quintanilla F, Celis‑Rosati A, Rodriguez‑Leiva C, Silva‑Navarro C, Silva‑Pinto Y, Toro‑Jeria B. [Effectiveness of a ketogenic diet in children with refractory epilepsy: a systematic review]. Rev Neurol. 2016 May 16;62(10):439–48.

Schwartz RH, Eaton J, Bower BD, Aynsley‑Green A. Ketogenic diets in the treatment of epilepsy: short‑term clinical effects. Dev Med Child Neurol. 1989 Apr;31(2):145–51.

Kossoff EH, Dorward JL. The modified Atkins diet. Epilepsia. 2008 Nov;49 Suppl 8:37–41.

Kossoff EH, Zupec‑Kania BA, Amark PE, Ballaban‑Gil KR, Bergqvist AGC, Blackford R, et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009 Feb 1;50(2):304–17.

Boison D. New insights into the mechanisms of the ketogenic diet. Curr Opin Neurol. 2017 Apr;30(2):187–92.

Gano LB, Patel M, Rho JM. Ketogenic diets, mitochondria, and neurological diseases. J Lipid Res. 2014 Nov;55(11):2211–28.

Huffman J, Kossoff EH. State of the ketogenic diet(s) in epilepsy. Curr Neurol Neurosci Rep. 2006 Jul;6(4):332–40.

Jeong EA, Jeon BT, Shin HJ, Kim N, Lee DH, Kim HJ, et al. Ketogenic diet‑induced peroxisome proliferator‑activated receptor‑γ activation decreases neuroinflammation in the mouse hippocampus after kainic acid‑induced seizures. Exp Neurol. 2011 Dec;232(2):195–202.

Masino S., Kawamura M, Wasser CD, Pomeroy L., Ruskin D. Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity. Curr Neuropharmacol. 2009 Sep;7(3):257–68.

Garriga‑Canut M, Schoenike B, Qazi R, Bergendahl K, Daley TJ, Pfender RM, et al. 2-Deoxy‑D-glucose reduces epilepsy progression by NRSF‑CtBP‑dependent metabolic regulation of chromatin structure. Nat Neurosci. 2006 Nov;9(11):1382–7.

Ahn Y, Narous M, Tobias R, Rho JM, Mychasiuk R. The ketogenic diet modifies social and metabolic alterations identified in the prenatal valproic acid model of autism spectrum disorder. Dev Neurosci. 2014;36(5):371–80.

Castro K, Baronio D, Perry IS, Riesgo RDS, Gottfried C. The effect of ketogenic diet in an animal model of autism induced by prenatal exposure to valproic acid. Nutr Neurosci. 2017 Jul;20(6):343–50.

Dai Y, Zhao Y, Tomi M, Shin B‑C, Thamotharan S, Mazarati A, et al. Sex‑Specific Life Course Changes in the Neuro‑Metabolic Phenotype of Glut3 Null Heterozygous Mice: Ketogenic Diet Ameliorates Electroencephalographic Seizures and Improves Sociability. Endocrinology. 2017 01;158(4):936–49.

Ruskin DN, Fortin JA, Bisnauth SN, Masino SA. Ketogenic diets improve behaviors associated with autism spectrum disorder in a sex‑specific manner in the EL mouse. Physiol Behav. 2017 Jan 1;168:138–45.

Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ. 2014 Mar 28;63(2):1–21.

Ruskin DN, Svedova J, Cote JL, Sandau U, Rho JM, Kawamura M, et al. Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS ONE. 2013;8(6):e65021.

Mychasiuk R, Rho JM. Genetic modifications associated with ketogenic diet treatment in the BTBRT+Tf/Jmouse model of autism spectrum disorder. Autism Res. 2017 Mar;10(3):456–71.

Smith J, Rho JM, Teskey GC. Ketogenic diet restores aberrant cortical motor maps and excitation‑to‑inhibition imbalance in the BTBR mouse model of autism spectrum disorder. Behav Brain Res. 2016 May 1;304:67–70.

Newell C, Johnsen VL, Yee NC, Xu WJ, Klein MS, Khan A, et al. Ketogenic diet leads to O‑GlcNAc modification in the BTBRT+tf/jmouse model of autism. Biochim Biophys Acta. 2017 Sep;1863(9):2274–81.

Newell C, Shutt TE, Ahn Y, Hittel DS, Khan A, Rho JM, et al. Tissue Specific Impacts of a Ketogenic Diet on Mitochondrial Dynamics in the BTBRT+tf/j Mouse. Front Physiol [Internet]. 2016 Dec 27 [cited 2018 Jul 26];7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5186794.

Newell C, Bomhof MR, Reimer RA, Hittel DS, Rho JM, Shearer J. Ketogenic diet modifies the gut microbiota in a murine model of autism spectrum disorder. Mol Autism. 2016;7(1):37.

de Theije CGM, Wopereis H, Ramadan M, van Eijndthoven T, Lambert J, Knol J, et al. Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav Immun. 2014 Mar;37:197–206.

Genestine M, Lin L, Durens M, Yan Y, Jiang Y, Prem S, et al. Engrailed-2 (En2) deletion produces multiple neurodevelopmental defects in monoamine systems, forebrain structures and neurogenesis and behavior. Hum Mol Genet. 2015 Oct 15;24(20):5805–27.

Kasprowska‑Liśkiewicz D, Liśkiewicz AD, Nowacka‑Chmielewska MM, Nowicka J, Małecki A, Barski JJ. The ketogenic diet affects the social behavior of young male rats. Physiol Behav. 2017 Oct 1;179:168–77.

Careaga M, Murai T, Bauman MD. Maternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates. Biol Psychiatry. 2017 01;81(5):391–401.

Ruskin DN, Murphy MI, Slade SL, Masino SA. Ketogenic diet improves behaviors in a maternal immune activation model of autism spectrum disorder. PLoS ONE. 2017;12(2):e0171643.

El‑Rashidy O, El‑Baz F, El‑Gendy Y, Khalaf R, Reda D, Saad K. Ketogenic diet versus gluten free casein free diet in autistic children: a case‑control study. Metab Brain Dis. 2017 Dec;32(6):1935–41.

Hurwitz S. The Gluten‑Free, Casein‑Free Diet and Autism: Limited Return on Family Investment. Journal of Early Intervention. 2013 Mar 1;35(1):3–19.

Mulloy A, Lang R, O’Reilly M, Sigafoos J, Lancioni G, Rispoli M. Addendum to “gluten‑free and casein‑free diets in treatment of autism spectrum disorders: A systematic review”. Research in Autism Spectrum Disorders. 2011 Jan 1;5(1):86–8.

Lee RWY, Corley MJ, Pang A, Arakaki G, Abbott L, Nishimoto M, et al. A modified ketogenic gluten‑free diet with MCT improves behavior in children with autism spectrum disorder. Physiol Behav. 2018 May 1;188:205–11.

Evangeliou A, Vlachonikolis I, Mihailidou H, Spilioti M, Skarpalezou A, Makaronas N, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol. 2003 Feb;18(2):113–8.

Herbert MR, Buckley JA. Autism and dietary therapy: case report and review of the literature. J Child Neurol. 2013 Aug;28(8):975–82.

Ermenlieva NM, Laleva KS, Tsankova GS, Hristova DN, Boyadzhiev VS, Todorova TT. Ketogenic diet – from the implementation in clinical practice to nowadays. J of IMAB. 2018 Feb 16;24(1):1904–8.

Kang HC, Chung DE, Kim DW, Kim HD. Early- and late‑onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004 Sep;45(9):1116–23.

Hallböök T, Sjölander A, Åmark P, Miranda M, Bjurulf B, Dahlin M. Effectiveness of the ketogenic diet used to treat resistant childhood epilepsy in Scandinavia. Eur J Paediatr Neurol. 2015 Jan;19(1):29–36.

Frye RE, Sreenivasula S, Adams JB. Traditional and non‑traditional treatments for autism spectrum disorder with seizures: an on‑line survey. BMC Pediatr. 2011 May 18;11:37.

Downloads

Published

2018-12-30

How to Cite

1.
Rajczewski A, Gibas-Dorna M. Ketogenic diet as possible therapy of autism spectrum disorder — review and implication. JMS [Internet]. 2018 Dec. 30 [cited 2024 Mar. 29];87(4):218-24. Available from: https://jms.ump.edu.pl/index.php/JMS/article/view/297

Issue

Section

Review Papers
Received 2018-07-27
Accepted 2018-09-28
Published 2018-12-30